Full-Time

Manufacturing Tech 3

Surgical Robotics OTTAVA

Posted on 5/9/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$57.5k - $92.6k/yr

Santa Clara, CA, USA

In Person

On-site role; schedule Monday–Friday, 6:00 AM–2:30 PM.

Category
Mechanical Engineering (2)
,
Requirements
  • Vocational Certificate, Technical, or Associate degree or equivalent required.
  • 4–5 years of experience in medical device or electromechanical capital equipment manufacturing, with demonstrated use of Good Documentation Practices in a regulated environment.
  • Strong mechanical aptitude with proven ability to troubleshoot and support root cause investigation of complex assemblies and system level issues.
  • Solid electrical troubleshooting capability, including proficiency with multimeters, grounding/isolation techniques, and diagnostic evaluation of module failures.
  • Ability to execute multiple assembly and testing tasks while consistently meeting workmanship, safety, and productivity expectations.
  • Knowledge of ESD principles and hands-on application of ESD controls in production environments.
  • Proficiency with precision assembly tools such as torque wrenches, screwdrivers, hand drivers, calipers, tweezers, multimeters, presses, IPA, and adhesives (e.g., Loctite).
  • Familiarity with ISO 13485, FDA QSR requirements, and clean manufacturing practices for medical device production.
  • Effective communication and collaboration skills with the ability to work across manufacturing, engineering, quality, and operations teams.
  • Ability to work independently in a fast-paced environment while managing priorities and supporting production continuity.
  • Flexibility to work overtime, early shifts, and weekends based on business needs.
  • Demonstrated initiative with a commitment to continuous improvement and adherence to GDP/GMP expectations.
Responsibilities
  • Perform advanced electro mechanical assembly and system level integration of robotic system modules including joints, control modules, sensors, and cable harnesses using detailed work instructions, and engineering documentation.
  • Operate within a structured production environment to meet daily build targets while maintaining compliance with ISO 13485, FDA QSR, and Good Documentation Practices requirements.
  • Interpret and apply assembly procedures, MPIs, TPIs, and engineering documents to correctly build, verify, and validate mechanical and electromechanical components across multiple product modules.
  • Conduct functional, electrical, mechanical, and diagnostic testing using calibrated equipment, test fixtures, torque tools, multimeters, and relevant software-based test procedures.
  • Troubleshoot, diagnose, and rework complex electrical and mechanical issues including alignment, sensor faults and calibration deviations and escalate systemic issues to engineering.
  • Maintain compliance with ESD protection requirements, clean manufacturing protocols, and contamination control standards appropriate for medical device manufacturing.
  • Accurately document production activities, inspection results, rework actions, and test outcomes in MES, ERP/SAP, and electronic DHR systems following GDP and GMP standards.
  • Perform in process inspections and contribute to quality verifications to ensure adherence to workmanship and regulatory standards.
  • Actively participate in quality improvement initiatives by identifying issues, supporting engineering in investigations, corrective and preventive action implementation.
  • Collaborate closely with Manufacturing leadership, NPI engineering, Quality, and Operations teams to resolve manufacturing challenges and support successful pilot builds and product introductions.
  • Provide detailed feedback to engineering teams for improving Manufacturing Work Instructions (MWI), Manufacturing Process Instructions (MPI), and Test Process Instructions (TPI), ensuring accuracy, clarity, and manufacturability.
  • Support training, knowledge-sharing, and on the job guidance for Manufacturing Technician I and II team members, including assistance with complex assemblies or troubleshooting tasks.
  • Maintain certification and demonstrate multi module proficiency across at least five major robotic system modules while upholding all safety, quality, and compliance requirements.
  • Prepare production lines by performing line clearance, verifying equipment maintenance and calibration status, and ensuring readiness for upcoming build operations.
  • Maintain accuracy of material transactions, perform cycle counts for raw materials, sub assemblies, and WIP, and ensure inventory integrity throughout the production workflow.
  • Identify and promptly report material shortages or discrepancies to Line Leads, Supervisors, and Managers to prevent build interruptions and support efficient production scheduling.
  • Contribute to process efficiency efforts by identifying workflow bottlenecks, recommending improvements, and supporting implementation of incremental process enhancements.
Desired Qualifications
  • Experience with robotics, motion-control systems, or surgical device assembly involving advanced troubleshooting.
  • Working knowledge of process validation activities (IQ/OQ/PQ) and fixture validation.
  • Exposure to continuous improvement methodologies and the ability to identify opportunities for workflow or process optimization.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.